Author:
Choueiri T.K.,Pal S.K.,McDermott D.F.,Morrissey S.,Ferguson K.C.,Holland J.,Kaelin W.G.,Dutcher J.P.
Reference30 articles.
1. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth;Yakes;Mol Cancer Ther,2011
2. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer;Kurzrock;J Clin Oncol,2011
3. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial;Smith;J Clin Oncol,2013
4. Targeting the Met signaling pathway in renal cancer;Giubellino;Expert Rev Anticancer Ther,2009
5. Metastatic renal cell carcinoma: many treatment options, one patient;Rini;J Clin Oncol,2009
Cited by
143 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献